Barclays Maintains an 'Underweight' on Arena Pharma (ARNA); Reports 4Q, Uncertainty Persists
Tweet Send to a Friend
Barclays maintains an 'Underweight' on Arena Pharma (NASDAQ: ARNA), PT $1.
Barclays analyst says, "We are maintaining our 3-Underweight rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "We are maintaining our 3-Underweight rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
